A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial

Who can take part

• Participant has completed treatment per protocol in a Novartis study of remibrutinib (unless otherwise specified in a parent study protocol) in a dermatological or allergology indication. Participants who derive benefit from the treatment with remibrutinib but have not completed the treatment in certain parent studies, due to parent study termination by Novartis, may be eligible if the termination was due to reasons other than safety or lack of efficacy (technical / administrative reasons). If a participant relapses during the treatment-free follow-up period of the parent protocol, he/she can enter this protocol immediately
• Participant is deriving benefit from remibrutinib, investigator believes he/she would continue to derive benefit from remibrutinib and the benefit outweighs the risk, based on the investigator’s judgement
• Participant is unable to obtain access to the marketed remibrutinib formulation per local post study drug supply program, prescription and/or reimbursement guidelines

Who cannot take part

• Use of prohibited medications as listed in Table 6-4 of study protocol
• Participant has prematurely discontinued study treatment in the parent study